Gene Editing & Reprogramming
Gene Editing
Our expertise in gene editing utilises CRISPR/Cas9 or TALEN technology to generate cell lines for in vitro modelling, with each cell line undergoing comprehensive quality control (QC) analysis to ensure you can obtain the best results with your cell line. Our gene editing experience includes:
- Single Base Pair Mutations: Introduction or removal of single bases, enabling the creation of perfect isogenic pairs.
- Gene Knock-outs: Precise removal of small gene segments to create out-of-frame deletions, leading to premature termination of protein expression.
- Sequence-Specific Deletions/Knock-outs: Targeted removal or introduction of repeat structures or domains within endogenous genes.
- Reporter Cell Lines: Insertion of reporters (e.g., GFP, RFP, resistance markers) as transcriptional or translational fusions.
- Inducible Gene Expression: Insertion of a gene-of-interest, controlled by an inducible promoter, into a safe-site locus such as AAVS1 or CLYBL.
- Inducible Gene Deletions: Using the CRE-Lox platform, gene deletions can be induced in differentiated cell lines when required.
With our advanced gene editing technologies and rigorous quality control, we are committed to providing you with reliable and precise cell lines for your research needs.
Reprogramming (Induced Pluripotent Stem Cells (iPSC) Technology)
We possess extensive experience in reprogramming primary cell types (e.g., fibroblasts, mesenchymal stem cells, peripheral blood mononuclear cells) into iPSC lines using non-integrative approaches.
Our services include establishing iPSC libraries with full QC analysis, ensuring high-quality standards.
- High-Efficiency Reprogramming: Using episomal plasmids or Sendai virus for optimal results.
- Quality Control Pipeline: Rigorous procedures to guarantee the production of high-quality iPSC lines.
Our reprogramming services leverage advanced iPSC technology to provide high-quality, reliable, and versatile cellular models for cutting-edge research and drug discovery.
For further information
please contact:
Dale Shelton, PhD
Director of Business